Patents by Inventor Shigeto Kawai
Shigeto Kawai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210293769Abstract: Provided are methods for culturing a cancer stem cell-derived tissue, which comprise the step of three-dimensionally culturing a cancer stem cell-derived tissue after treating it with a therapeutic agent for diseases. The culture methods of the present disclosure enable the construction of cell clusters analogous to therapeutic agent-resistant tissues which are characteristically seen in tissues of patients who have actually been administered with a therapeutic agent for diseases. The cell clusters of the present disclosure are useful for elucidating the mechanism for acquiring anticancer agent resistance, identifying a therapeutic target therefor, or screening for a therapeutic agent. The preferred disease in the present disclosure is cancer.Type: ApplicationFiled: August 8, 2019Publication date: September 23, 2021Inventors: Shigeto KAWAI, Masaki YAMAZAKI, Kiyotaka NAKANO, Masami SUZUKI, Tatsumi YAMAZAKI
-
Patent number: 10696743Abstract: Methods that involve detection of a DSG3 protein for diagnosing cancer are disclosed. In lung cancer, the expression of DSG3 was found to be enhanced at very high frequency at the gene level and protein level. Methods of the present invention can be carried out using an antibody that recognizes a DSG3 protein. Pharmaceutical compositions, cell growth inhibitors, and anticancer agents containing a DSG3-binding antibody as an active ingredient are also disclosed. Methods of inducing cell damage in DSG3-expressing cells and methods of suppressing proliferation of DSG3-expressing cells by contacting the DSG3-expressing cells with DSG3-binding antibodies are also disclosed.Type: GrantFiled: February 10, 2017Date of Patent: June 30, 2020Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Hiroyuki Aburatani, Shunpei Ishikawa, Hirotaka Ito, Kiyotaka Nakano, Shigeto Kawai
-
Publication number: 20180155438Abstract: Disclosed is a monoclonal antibody binding to an ITM2A protein. This antibody is useful in the diagnosis, prevention, and treatment of cancer such as Ewing's sarcoma, T cell leukemia, T cell lymphoma, acute myeloid leukemia, B cell tumor, and multiple myeloma. The present invention also provides a pharmaceutical composition, a cell growth inhibitor, and an anticancer agent containing the antibody as an active ingredient, and a method for treating cancer, a method for predicting the efficacy of cancer treatment, and a method for determining the presence of cancer in a test subject using the antibody.Type: ApplicationFiled: January 24, 2018Publication date: June 7, 2018Applicants: THE UNIVERSITY OF TOKYO, CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Hiroyuki ABURATANI, Shumpei ISHIKAWA, Shigeto KAWAI
-
Patent number: 9920129Abstract: Disclosed is a monoclonal antibody binding to an ITM2A protein. This antibody is useful in the diagnosis, prevention, and treatment of cancer such as Ewing's sarcoma, T cell leukemia, T cell lymphoma, acute myeloid leukemia, B cell tumor, and multiple myeloma. The present invention also provides a pharmaceutical composition, a cell growth inhibitor, and an anticancer agent containing the antibody as an active ingredient, and a method for treating cancer, a method for predicting the efficacy of cancer treatment, and a method for determining the presence of cancer in a test subject using the antibody.Type: GrantFiled: April 29, 2016Date of Patent: March 20, 2018Assignees: THE UNIVERSITY OF TOKYO, CHUGAI SEIY AKU KABUSHIKI KAISHAInventors: Hiroyuki Aburatani, Shumpei Ishikawa, Shigeto Kawai
-
Patent number: 9751942Abstract: A monoclonal antibody recognizing the extracellular region of LAMP5 was produced. The produced antibody demonstrated antibody-dependent cell-mediated cytotoxic activity, and/or cell growth inhibitory activity in the presence of a toxin-labeled secondary antibody, against a multiple myeloma cell line.Type: GrantFiled: March 29, 2013Date of Patent: September 5, 2017Assignee: CHUGAI SEIYAKU KABUSHIKI KAISHAInventor: Shigeto Kawai
-
Patent number: 9733245Abstract: An objective of the present invention is to provide chimeric receptors containing a mouse Fc? receptor extracellular domain and a human Fc? receptor transmembrane domain, or chimeric receptors containing a mouse Fc? receptor extracellular domain and a human ? chain transmembrane domain. Another objective of the present invention is to provide methods for measuring the ADCC activity of mouse antibodies and methods of screening for mouse antibodies having ADCC activity, using the chimeric receptors. To accomplish the above-mentioned objectives, the present inventors produced chimeric molecules by fusing the extracellular domain of mouse Fc?R3 or mouse Fc?R4 with the transmembrane domain/intracellular domain of human ? chain or human Fc?R3, and expressed the chimeric molecules in human NK92 cells.Type: GrantFiled: December 1, 2014Date of Patent: August 15, 2017Assignee: Chugai Seiyaku Kabushiki KaishaInventor: Shigeto Kawai
-
Publication number: 20170152314Abstract: Methods that involve detection of a DSG3 protein for diagnosing cancer are disclosed. In lung cancer, the expression of DSG3 was found to be enhanced at very high frequency at the gene level and protein level. Methods of the present invention can be carried out using an antibody that recognizes a DSG3 protein. Pharmaceutical compositions, cell growth inhibitors, and anticancer agents containing a DSG3-binding antibody as an active ingredient are also disclosed. Methods of inducing cell damage in DSG3-expressing cells and methods of suppressing proliferation of DSG3-expressing cells by contacting the DSG3-expressing cells with DSG3-binding antibodies are also disclosed.Type: ApplicationFiled: February 10, 2017Publication date: June 1, 2017Inventors: Hiroyuki ABURATANI, Shunpei Ishikawa, Hirotaka Ito, Kiyotaka Nakano, Shigeto Kawai
-
Publication number: 20160311920Abstract: Disclosed is a monoclonal antibody binding to an ITM2A protein. This antibody is useful in the diagnosis, prevention, and treatment of cancer such as Ewing's sarcoma, T cell leukemia, T cell lymphoma, acute myeloid leukemia, B cell tumor, and multiple myeloma. The present invention also provides a pharmaceutical composition, a cell growth inhibitor, and an anticancer agent containing the antibody as an active ingredient, and a method for treating cancer, a method for predicting the efficacy of cancer treatment, and a method for determining the presence of cancer in a test subject using the antibody.Type: ApplicationFiled: April 29, 2016Publication date: October 27, 2016Applicants: THE UNIVERSITY OF TOKYO, CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Hiroyuki ABURATANI, Shumpei ISHIKAWA, Shigeto KAWAI
-
Patent number: 9274119Abstract: The present invention relates to an antibody binding to Claudin6 (CLDN6) expressed on a cell membrane. The antibody of the present invention recognizes human CLDN6 present in a native form on cell membrane surface and exhibits cytotoxicity through ADCC and/or CDC activities against cancer cell lines highly expressing human CLDN6. Moreover, the antibody of the present invention has cell growth inhibitory effect through conjugation with toxin on cancer cell lines highly expressing human CLDN6. The human CLDN6 is overexpressed in tumor tissues (lung adenocarcinoma, gastric cancer, and ovarian cancer), although its expression is not observed in normal tissues. Thus, the anti-CLDN6 antibody is expected to highly accumulate in tumors highly expressing human CLDN6 and can serve as a very effective antitumor agent.Type: GrantFiled: January 9, 2009Date of Patent: March 1, 2016Assignees: THE UNIVERSITY OF TOKYO, CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Hiroyuki Aburatani, Shuichi Tsutsumi, Kunihiro Nishimura, Hirofumi Sakumoto, Shigeto Kawai
-
Patent number: 9139647Abstract: The present invention relates to an antibody binding to a TM4SF20 protein and the diagnosis and treatment of cancer using the antibody. Specifically, the present invention provides an anti-TM4SF20 antibody and a pharmaceutical composition (e.g., an anticancer agent and a diagnostic drug for cancer) comprising the antibody as an active ingredient.Type: GrantFiled: December 25, 2009Date of Patent: September 22, 2015Assignees: FORERUNNER PHARMA RESEARCH CO., LTD., THE UNIVERSITY OF TOKYOInventors: Hiroyuki Aburatani, Shunpei Ishikawa, Shigeto Kawai
-
Publication number: 20150259417Abstract: An antibody capable of binding to a specific region of glypican 3, as well as a humanized antibody created based on that antibody are disclosed. The anti-GPC3 antibody of the invention has a higher ADCC activity and CDC activity compared with those of a conventional antibody. The antibody of the present invention is useful as a cell growth inhibitor, an anticancer agent and an agent for diagnosis of cancers.Type: ApplicationFiled: May 15, 2015Publication date: September 17, 2015Inventors: Kiyotaka Nakano, Takeshi Yoshino, Jun-Ichi Nezu, Hiroyuki Tsunoda, Tomoyuki Igawa, Hiroko Konishi, Megumi Tanaka, Izumi Sugo, Shigeto Kawai, Takahiro Ishiguro, Yasuko Kinoshita
-
Publication number: 20150118184Abstract: A monoclonal antibody recognizing the extracellular region of LAMP5 was produced. The produced antibody demonstrated antibody-dependent cell-mediated cytotoxic activity, and/or cell growth inhibitory activity in the presence of a toxin-labeled secondary antibody, against a multiple myeloma cell line.Type: ApplicationFiled: March 29, 2013Publication date: April 30, 2015Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventor: Shigeto Kawai
-
Publication number: 20150079610Abstract: An objective of the present invention is to provide chimeric receptors containing a mouse Fc? receptor extracellular domain and a human Fc? receptor transmembrane domain, or chimeric receptors containing a mouse Fc? receptor extracellular domain and a human ? chain transmembrane domain. Another objective of the present invention is to provide methods for measuring the ADCC activity of mouse antibodies and methods of screening for mouse antibodies having ADCC activity, using the chimeric receptors. To accomplish the above-mentioned objectives, the present inventors produced chimeric molecules by fusing the extracellular domain of mouse Fc?R3 or mouse Fc?R4 with the transmembrane domain/intracellular domain of human ? chain or human Fc?R3, and expressed the chimeric molecules in human NK92 cells.Type: ApplicationFiled: December 1, 2014Publication date: March 19, 2015Inventor: SHIGETO KAWAI
-
Patent number: 8946385Abstract: An objective of the present invention is to provide chimeric receptors containing a mouse Fc? receptor extracellular domain and a human Fc? receptor transmembrane domain, or chimeric receptors containing a mouse Fc? receptor extracellular domain and a human ? chain transmembrane domain. Another objective of the present invention is to provide methods for measuring the ADCC activity of mouse antibodies and methods of screening for mouse antibodies having ADCC activity, using the chimeric receptors. To accomplish the above-mentioned objectives, the present inventors produced chimeric molecules by fusing the extracellular domain of mouse Fc?R3 or mouse Fc?R4 with the transmembrane domain/intracellular domain of human ? chain or human Fc?R3, and expressed the chimeric molecules in human NK92 cells.Type: GrantFiled: January 30, 2008Date of Patent: February 3, 2015Assignee: Chugai Seiyaku Kabushiki KaishaInventor: Shigeto Kawai
-
Patent number: 8846870Abstract: The present invention provides antibodies that bind to HS6ST2 proteins, pharmaceutical compositions comprising the antibodies as active ingredients, methods for diagnosing cancer using the antibodies, HS6ST2 proteins conjugated to cytotoxic agents and pharmaceutical compositions comprising the HS6ST2 proteins as active ingredients.Type: GrantFiled: December 22, 2009Date of Patent: September 30, 2014Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Shigeto Kawai, Naoki Kimura
-
Publication number: 20140193420Abstract: Disclosed is a monoclonal antibody binding to an ITM2A protein. This antibody is useful in the diagnosis, prevention, and treatment of cancer such as Ewing's sarcoma, T cell leukemia, T cell lymphoma, acute myeloid leukemia, B cell tumor, and multiple myeloma. The present invention also provides a pharmaceutical composition, a cell growth inhibitor, and an anticancer agent containing the antibody as an active ingredient, and a method for treating cancer, a method for predicting the efficacy of cancer treatment, and a method for determining the presence of cancer in a test subject using the antibody.Type: ApplicationFiled: April 18, 2012Publication date: July 10, 2014Applicants: CHUGAI SEIYAKU KABUSHIKI KAISHA, THE UNIVERSITY OF TOKYOInventors: Hiroyuki Aburatani, Shumpei Ishikawa, Shigeto Kawai
-
Patent number: 8603481Abstract: A therapeutic agent for solid tumors, the agent comprising as an active ingredient, an antibody that specifically binds to a protein having the amino acid sequence represented by SEQ ID NO:2 or an antibody fragment maintaining the antibody activity.Type: GrantFiled: October 7, 2004Date of Patent: December 10, 2013Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Shigeto Kawai, Masahiko Mihara, Yasuo Koishihara
-
Patent number: 8158385Abstract: To identify antigens of the 2D7 antibody, the present inventors cloned the 2D7 antigen. The results suggested that the 2D7 antigen is an HLA class I molecule. Based on this finding, the present inventors examined whether the 2D7 antibody has cell death-inducing activity. Nuclei fragmentation was observed when the 2D7 antibody was cross-linked with another antibody, indicating that cell-death was induced. Further, diabodies of the 2D7 antibody were found to have very strong cell death-inducing activities, even without the addition of another antibody. These results indicate that minibodies of an HLA-recognizing antibody can be used as cell death-inducing agents.Type: GrantFiled: October 10, 2003Date of Patent: April 17, 2012Assignees: Chugai Seiyaku Kabushiki KaishaInventors: Shuji Ozaki, Masahiro Abe, Masayuki Tsuchiya, Naoki Kimura, Shigeto Kawai
-
Publication number: 20120004117Abstract: The present invention relates to an antibody binding to a TM4SF20 protein and the diagnosis and treatment of cancer using the antibody. Specifically, the present invention provides an anti-TM4SF20 antibody and a pharmaceutical composition (e.g., an anticancer agent and a diagnostic drug for cancer) comprising the antibody as an active ingredient.Type: ApplicationFiled: December 25, 2009Publication date: January 5, 2012Applicants: Forerunner Pharma Research Co., Ltd., The University of TokyoInventors: Hiroyuki Aburatani, Shunpei Ishikawa, Shigeto Kawai
-
Publication number: 20110262929Abstract: The present invention provides antibodies that bind to HS6ST2 proteins, pharmaceutical compositions comprising the antibodies as active ingredients, methods for diagnosing cancer using the antibodies, HS6ST2 proteins conjugated to cytotoxic agents and pharmaceutical compositions comprising the HS6ST2 proteins as active ingredients.Type: ApplicationFiled: December 22, 2009Publication date: October 27, 2011Applicant: FORERUNNER PHARMA RESEARCH CO., LTD.Inventors: Shigeto Kawai, Naoki Kimura